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Transfusion-transmissible infections and transfusion-related
immunomodulation
Abstract
The risk of acquiring a transfusion-transmitted infection has declined in recent years. However, after
human immunodeficiency virus and hepatitis B and C virus transmission were successfully reduced,
new pathogens are threatening the safety of the blood supply, especially in the face of rising numbers of
immunocompromised transfusion recipients. Despite new standards in the manufacture and storage of
blood products, bacterial contamination still remains a considerable cause of transfusion-related
morbidity and mortality. Better allograft survival in kidney transplant patients and higher cancer
recurrence rate in surgical oncology patients after allogeneic blood transfusions highlighted a previously
underestimated side-effect: transfusion-related immunomodulation (TRIM). The precise
pathomechanism still remains uncertain; however, its mostly deleterious effects--such as a higher
incidence of postoperative or nosocomial infections--is increasingly accepted. Although
transfusion-related immunomodulation is thought to be mediated mainly by donor white blood cells, the
benefit of leukoreduction on overall mortality and on infectious complications is highly debatable.
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Abstract 
 
The risk of acquiring a transfusion-transmitted infection has declined in recent years. 
However, after human immunodeficiency virus and hepatitis B and C virus transmission were 
successfully reduced, new pathogens are threatening the safety of blood supply, especially in 
the face of a rising number of immunocompromised transfusion recipients. Despite new 
standards in blood product manufacturing and storage, bacterial contamination still remains a 
considerable cause of transfusion-related morbidity and mortality. 
Better allograft survival in kidney transplant patients and higher cancer recurrence rate in 
surgical oncology patients after allogeneic blood transfusions highlighted a previously 
underestimated side effect: transfusion-related immunomodulation. The precise 
pathomechanism still remaining uncertain, however, it’s mostly deleterious effects such as a 
higher incidence of postoperative or nosocomial infections is increasingly accepted. Although 
transfusion-related immunomodulation is thought to be mainly mediated by donor white 
blood cells, the benefit of leukoreduction on overall mortality and on infectious complications 
is highly debated.  
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For decades blood components were transfused in order to maintain an arbitrary haemoglobin 
threshold of 10 g/dL [1, 2], a thrombocyte count superior to 20’000 per µL [3] or to correct 
any coagulopathy [4]. Despite little medical evidence documenting the efficacy of 
prophylactic transfusions, they are associated with significant adverse effects [5]. The 
potential harm of a liberal transfusion strategy has been largely demonstrated [6], [7]. 
Nowadays there are three main risks for transfusion-related morbidity and mortality: a) 
incorrect blood component transfusions (70%), b) transfusion-transmissible infections (2%), 
and c) immunologic risks (28%) [8]. Incorrect blood component transfusions, although 
entirely preventable, remain the most frequent reported transfusion hazard with a 1’000 to 
10’000 times higher frequency than the risk of viral infection from blood [9]. Standardized 
surveillance systems have been implemented to reduce the risk of administrative errors 
(leading to ABO-incompatible blood transfusion) [10]. Transfusion-transmissible infections, 
immunologic risks and nosocomial infections associated with blood transfusions will be 
reviewed in this article. 
 
 
I. Transfusion-transmitted infections 
 
Transfusion-transmitted infections due to a variety of agents, although rare, still demonstrate a 
serious risk in allogeneic blood transfusions [11]. In Western Countries the implicated 
pathogens are mainly viruses and bacteria, rarely parasites, and prion transmission has very 
likely occurred in a few documented cases.  
1. Viruses 
 
Virus transmission may be related to leukocytes contained in blood products such as 
cytomegalovirus, Epstein-Barr virus, human herpes virus 6-8, human T-cell leukaemia / 
lymphoma virus [12]. Conversely, other viruses are not exclusively cell bound such as HIV, 
hepatitis B and C viruses, Parvovirus B19, West Nile virus [13], TT virus [14], SEN virus 
[15]. 
 
Of all human herpes viruses, cytomegalovirus [CMV] is the most significant cause of 
transfusion-associated morbidity and mortality. The problem of transfusion-associated CMV 
infection differs from that of other transfusion-transmitted infections in that only certain 
groups of patients require CMV-free blood or blood components, i.e. seronegative pregnant 
women and their newborn babies, seronegative recipients of allogeneic bone marrow 
transplants from seronegative donors, individuals with AIDS, and other profoundly 
immunocompromised patients. CMV prevalence in the population ranges from 40% to 100%, 
determined by geographic and socioeconomic factors. The virus is confined to leukocytes in 
latently infected blood donors and can be reactivated after transfusion, resulting in an 
infection rate of 1%-12% among adults, of 20% among neonates, and as high as 57% among 
bone marrow transplant recipients [16]. Infection can result in retinitis, pneumonitis, hepatitis, 
gastroenteritis, and death. CMV infection in risk groups can be minimized by selection of 
CMV-seronegative donors. Since transmission of CMV from seropositive donors by blood 
components containing fewer than 5x 10^6 leukocytes per unit is unlikely, leukodepletion is 
an effective alternative to the use of seronegative blood products [17]. In countries, where 
only leukocyte-filtered blood products are available today, the incidence of CMV transfusion-
related infections has significantly fallen after white blood cell reduction has been 
implemented [18].  
Epstein-Barr virus [EBV] is the causative agent of infectious mononucleosis, Burkitt 
lymphoma, nasopharyngeal carcinoma, and associated with other lymphoproliferative 
diseases (i.e. Hodgkin lymphoma, oral hairy leukoplakia). The incidence of latent EBV 
infection in the general population is approximately 90%. EBV-seronegative blood 
transfusion recipients who are immunocompromised are at risk of acquiring EBV infection. 
Several cases of transfusion-associated EBV disease, including lymphoproliferative disease, 
have been reported [19]. However, the relatively rare rate of transmission via transfusion does 
not justify screening for virus-free donor blood. Besides that, research showed that 
leukoreduction eliminated the PCR signal in 15 of 16 units of EBV-contaminated blood with 
none of the 15 EBV-negative patients who received the transfusions that had undergone 
leukoreduction experienced seroconversion [20]. 
 
Other viral agents are not exclusively cell bound and transmitted with any contaminated blood 
product (HIV, hepatitis B and C viruses). Besides the well known transfusion-transmitted 
viral agents, new viruses have recently been identified in transfusion-transmitted infections 
(West Nile virus [13], TT virus [14], SEN virus [15]). 
 
Improvements in donor screening and testing and viral inactivation of plasma derivatives (by 
methylene blue or solvent-detergent treatment [21]) have resulted in substantial declines in 
transfusion-transmitted infections over the last two decades. Most recently, nucleic acid 
testing techniques have been developed to screen blood and plasma donations for evidence of 
very recent viral infections that could be missed by conventional serologic tests [22]. The risk 
of viral disease transmission has nowadays become so small that mathematical models are 
used to assess it. For example, the residual risk of a transfusion-transmitted HIV infection is 1 
per 7.8 million donations, and for hepatitis C virus infection 1 per 2.3 million donations. 
Since nucleic acid testing is not available for hepatitis B virus, the residual risk of a 
transfusion-transmitted infection is still 1 per 153,000 donations [23].   
 
Parvovirus B19 is a common human pathogen that is more and more seen as a new threat to 
the safety of blood supply. The main route of transmission is through respiratory vesicles, 
with a majority of infections occurring during childhood and manifesting as erythema 
infectiosum. Parvovirus B19 can also be transmitted via blood transfusion and organ 
transplantation. The majority of adult populations show immunological evidence of a 
previous exposure to parvovirus B19. Although the immune response is able to clear infection 
and provide life-long protection against parvovirus B19, recent data suggest that in some, if 
not the majority, of individuals the acute phase of infection is followed by viral persistence in 
the blood or other tissues regardless of the host's immunocompetence. Transmission of 
parvovirus B19 by blood products and its resistance to common viral inactivation methods 
raises several blood safety questions, still unanswered. The diversity of parvovirus B19 strains 
and the ability of the virus to persist in the presence of specific antibodies raise the issue of 
transmissibility by transfusion not so much to immunocompetent recipients but rather to the 
large proportion of recipients in whom there is some degree of immunodeficiency [24]. 
 
 
2. Bacteria 
 
Transfusion-transmitted infections through bacteria are mainly the result of bacterial 
contamination of blood products. In the past the safety of blood transfusions could be 
enhanced through modern phlebotomy practices (arm cleansing using an iodine / alcohol mix, 
and diverting the first 50ml of each blood donation), refrigeration of red cells, freezing of 
plasma and improved materials for transfusion product collection and storage [25]. However, 
one in every 3000 units of donated blood is still contaminated with bacteria. Clinically 
significant sepsis results from 1 of every 250’000 red blood cell units transfused. Platelet 
concentrates are particularly vulnerable to bacterial contamination because their storage 
temperature (20-24°C) readily facilitates growth. Approximately 1 in every 2000 platelet 
concentrates is contaminated and 1 in every 25’000 platelet concentrates has been reported to 
cause sepsis [26]. Obviously, the risk of transfusion-transmitted bacterial infection is 
significantly higher than for transfusion-transmitted viral infections [27]. Implicated 
pathogens are mainly skin-commensal bacteria like Staphylococcus spp., Streptococcus spp. 
and Serratia spp. [28]. Quality control testing for bacterial contamination of platelet products 
by culturing samples under aerobic conditions until the end of the product shelf life has been 
effective in identifying and preventing the transfusion of bacterially contaminated platelet 
units [29].  
 
Several studies have shown a higher incidence of nosocomial infections in transfused versus 
untransfused patients. Since the implicated pathomechanism is rather due to transfusion-
related immunomodulation and secondary bacterial infection than to direct inoculation 
through a bacteria containing blood product, nosocomial infection after transfusion will be 
discussed in the chapter of transfusion-related immunomodulation. 
 
 
3. Parasites 
 
In Western Countries protozoal transfusion-transmitted infections are rather rare. However, 
on a global scale malaria remains one of the most common transfusion-transmitted infections 
[30]. With more and more people travelling to endemic areas, the number of donors who have 
a potential ‘malaria risk’ is increasing, and there is corresponding pressure on the collection 
teams to correctly and effectively identify all such ‘malaria-risk’ individuals, and pressure on 
the recruitment staff to replace the donations lost, even if deferral is only temporary. Although 
the examination of blood films is still the basis for diagnosing acute malaria, it is not 
sufficiently sensitive for blood bank screening. In non-endemic countries, donor deferral in 
combination with screening for specific antimalarial immunoglobulin provides an effective 
means of minimizing the risk of transmission. In endemic countries, more specific donor 
questioning, consideration of seasonal variation and geographical distribution may help to 
identify the population of donors who are most likely to be infected. In addition, the 
administration of antimalarials to transfusion recipients may help to prevent transmission. 
Although rare and prevented by donor deferral and immunoglobulin testing, it is likely that 
cases of transfusion-transmitted malaria may still occur in non-endemic areas. Therefore 
malaria must always be considered in any patient with a post-transfusion febrile illness.  
 
Primary toxoplasmosis has been reported to be transmitted from seropositive donors to 
immunocompromised recipients [31]. Other transfusion-transmitted protozoal pathogens 
include Leishmania and Trypanosoma. With a very low prevalence in Western Countries 
there is currently no donor screening for both of them. However, transfusion-transmitted 
infection by Leishmania or Trypanosoma seems to be successfully prevented by 
leukoreduction [32], [33]. 
 
 
4. Prions 
 
Besides transfusion-transmitted infections through viral, bacterial or protozoal pathogens, 
there is growing concern about the risk of blood-borne transmission of variant Creutzfeldt-
Jakob disease (vCJD). Four cases of packed red blood cell transfusion-transmitted vCJD 
have been described [34], [35], [36], [37]. No case of prion transmission by plasma products 
has been observed yet. Measures implemented in various countries and several technical 
factors may contribute to the prevention of prion transmission. Those measures include (a) the 
epidemiological surveillance of population in countries with cases of vCJD and/or bovine 
spongiform encephalopathy (BSE), (b) the deferral of blood donors who travelled or resided 
to countries with BSE, or who received transfusion or tissue transplant, (c) leukocyte 
reduction, and (d) the removal of the prion agents during the complex industrial fractionation 
process used to prepare plasma products [38]. 
 
Thanks to strict exclusion criteria for blood donors, improved transfusion product collection 
and storage practices, immunoglobulin and nucleic acid testing, and viral inactivation, the 
transfusion-transmitted infectious risk has declined significantly in the last decade. The 
implementation of leukoreduction in many countries has further improved blood transfusion 
safety. 
 
Practice Points:  
• New standards in blood product manufacturing and storage reduce the risk of 
transfusion-transmitted infections. 
• Mainly in immunocompromised patients transfusion-transmitted viral infections still 
remain a considerable cause of transfusion-related morbidity and mortality. 
• Bacterial contamination of a blood product, mainly concentrates of thrombocytes 
stored at 20-24°C, is the single most often encountered source of a transfusion-related 
infection. 
• Leukoreduction reduces primary transmission of CMV and other infections due to 
WBC-associated pathogens. 
 
 Research Agenda: 
• Further research is warranted to develop new manufacturing techniques to inactivate 
pathogens contained in the donated blood and to prevent secondary bacterial 
contamination of processed blood products   
 
 
 
II. Transfusion-related immunomodulation (TRIM) 
 
In 1973 Opelz et al. suspected an immunomodulating effect of red blood cell (RBC) 
transfusions to explain the better outcome of patients that had received blood transfusions 
prior to kidney transplant [39]. This immunosuppressive effect of RBC transfusions was 
confirmed by animal data and observational clinical studies, and in 1981 Gantt et al. 
suggested the possibility of an association between RBC transfusions and increased cancer 
recurrence [40]. Since then, more than a hundred clinical studies examined the possible 
adverse effect of RBC transfusions on cancer recurrence. Although it is now accepted that 
transfusions are associated with poorer prognosis in surgical cancer patients, the exact 
mechanism remains unclear [41]. Besides a higher recurrence rate of resected malignancies, 
transfused patients also show an increased incidence of nosocomial infections [42]. The 
incriminated pathomechanism of these mostly adverse effects of blood transfusions is called 
transfusion-related immunomodulation (TRIM).  
 
 
 
1. Alloimmunization, tolerance, or immunosuppression 
 
Allogeneic blood transfusions (ABTs) may either cause alloimmunization, tolerance, or 
immunosuppression in recipients. The specific immunomodulatory constituents are still 
unknown, though several are highly suspected: allogeneic mononuclear cells, HLA peptides, 
and soluble biologic response modifiers.  
 
 
Alloimmunization 
 
Allogeneic blood transfusions introduce a multitude of foreign antigens into the recipient, 
including allogeneic mononuclear cells with cell-bound HLA antigens. In general, fully 
HLA-mismatched transfusions lead to alloimmunization, while allogeneic transfusions 
sharing at least one HLA antigen with the recipient induce tolerance and to some degree 
immunosuppression [43].  
In the patient population of acute myeloid leukemia alloimmunization with development of 
alloantibodies and of refractoriness to platelet transfusions was shown to be dependent on the 
white blood cell count and / or the functional status of transfused white blood cells [44]. The 
patients received either platelets obtained by apheresis from single random donors, pooled 
concentrates from random donors that had been leukocyte-reduced by filtration, or pooled 
concentrates from random donors whose leukocytes had been inactivated by ultraviolet B 
irradiation. There were no significant differences among the three treated groups in any study 
end point. However, all three types of treated platelets significantly reduced the development 
of lymphocytotoxic antibodies and alloimmune refractoriness to platelet transfusions, as 
compared with untreated, pooled platelet concentrates from random donors. This is consistent 
with the result of a meta-analysis showing that the rates of lymphocytotoxic antibodies in 
patients who had received transfusions were lower in patients given leukocyte-reduced 
platelets and red cells than in controls who received standard blood components [45]. 
 
 
Tolerance 
 
Transfused white blood cells (WBCs) with a partially matched HLA-pattern are protected 
from immunologic clearing through host defence mechanisms (tolerance) since the host 
immune system fails to recognize them as foreign. Besides that, it is also believed that 
allogeneic plasma containing soluble HLA antigens may enter the recipient’s thymic 
circulation, producing clonal deletion of the recipient’s T cells that are directed against 
allogeneic donor antigens [46]. In the clinical setting of recurrent spontaneous abortions, 
successful outcome of the next pregnancy was significantly more common in women injected 
with purified lymphocytes prepared from their husbands' blood than in those injected with 
their own lymphocytes. It is postulated that through the HLA-alloimmunization by the 
father’s lymphocytes the embryos were no longer recognized as foreign by the mother’s 
immune system and less frequently aborted [47]. 
 
In addition to the degree of HLA compatibility between donor and recipient, the 
immunogenicity of cellular or soluble HLA antigens depends on the viability of the donor 
antigen-presenting cells and the presence of co-stimulatory signals for the presentation of the 
donor antigens to the recipient’s T-cells. Non-viable antigen-presenting cells and / or the 
absence of the requisite co-stimulatory signals result in T-cell unresponsiveness (anergy) and 
immune tolerance [48], [49], [50], [51].  
 
 
Immunosuppression 
 
HLA compatibility between donor and recipient may result in the persistence of allogeneic 
donor WBCs in the recipient (microchimerism) [52]. Microchimerism leads to the release of 
interleukins (IL-4, IL-10, and TGF-β) that inhibit the T-helper cell type 1 (Th-1)-mediated 
immune response. Impairment of Th-1 cytokine secretion (IL-2, IL-12, and interferon-γ) 
results in impairment of various functions of cellular immunity (including antigen 
processing, macrophage activation, T-cell cytotoxic function through CD 8 positive T-cells, 
and the neutrophils and monocyte cytocidal activity) [53]. The result is a shift toward a T-
helper cell type-2 (Th-2) immune response favouring humoral immunity. This partially 
suppressed Th-1-mediated cytotoxic immune response is thought to be the underlying 
mechanism of the beneficial effect of blood transfusions in Crohn’s disease patients with a 
statistically significant reduction in disease recurrence and a longer disease free interval [54].  
 
Transfusion-associated microchimerism has been detected and studied in severely injured, 
transfused patients. Injury induces an immunosuppressive and inflammatory milieu in which 
replication-competent leukocytes of fresh blood products may persist in the recipient’s blood. 
Transfusion-associated microchimerism is present in approximately 50% of transfused 
severely injured patients at hospital discharge and is not affected by leukoreduction [55]. It is 
postulated that, if the conditions are right for transfusion-associated microchimerism to 
develop, engraftment occurs with a very small number of pluripotent hematopoietic cells, 
regardless of the total number of donor WBCs present. It is possible that a relative paucity 
specifically of donor antigen-presenting cells (as might occur with leukoreduction) might 
limit the stimulation of the recipient’s cellular immune response, in turn leading to a greater 
likelihood of developing microchimerism than would be expected based purely on the total 
number of donor WBCs transfused [56]. In approximately 10% of patients, the chimerism 
from a single blood donor may increase in magnitude over months to years, reaching as much 
as 2% to 5% of all circulating leukocytes [57].  
 
In a most negative way, in transfusion-related immunosuppressed recipients, microchimerism 
may result in the development of transfusion-associated graft-versus-host disease 
(TAGVHD). It is a rare (approximately 1:1 million units transfused) but potentially lethal 
complication with a mortality rate > 90%, in which immunocompetent donor cells proliferate 
and attack host hemopoietic cells, skin, liver, and bile duct epithelial cells. Although more 
common in immunocompromised patients, the risk factors for the development of graft-
versus-host disease include transfusions from donors with a similar HLA-pattern, the use of 
relatives as donors, male recipients, and fresh blood containing viable lymphocytes [58].  
 
Biologic response modifiers accumulating in blood components during storage have been 
implicated in the pathogenesis of TRIM. These mediators are contained in intracellular WBC 
granules, and are released in a time-dependent manner as the WBCs deteriorate during storage 
[59]. It has been shown that at least some of these biologic response modifiers (histamine, 
eosinophil cationic protein, eosinophil protein X, TGF-β) may contribute to the development 
of immunosuppression and tissue damage by inhibition of neutrophils, cytotoxic T-cells and 
natural killer cells [60], [61], [62], [63]. 
 
 
2. Pro-inflammatory state after blood transfusion 
 
Research on transfusion-related acute lung injury (TRALI) raised the suspicion that ABTs 
in general and WBC-containing ABTs in particular mediate their deleterious effect through a 
pro-inflammatory mechanism. The findings of several observational clinical studies, showing 
a higher incidence of multiple organ failure in transfused versus untransfused patients, seem 
to support this hypothesis. The precise mechanism of this pro-inflammatory state after ABTs 
is unclear, but most evidence suggests that tissue injury with consequent pulmonary oedema 
is mediated by reactive oxygen species and proteolytic enzymes released from activated 
neutrophils [64]. In the context of TRALI, bioactive lipids and cytokines that accumulate 
during storage of blood products are supposed to prime recipient’s neutrophils and activate 
pulmonary endothelial cells – a mechanism called “non-immune TRALI” [65].  
In what is called “immune TRALI”, donor’s alloantibodies directed against Human 
Leukocyte Antigens (HLA) or Human Neutrophil Antigens (HNA) bind to recipient’s 
neutrophils and activate them. After pooling in the pulmonary vasculature, the activated 
neutrophils release inflammatory mediators that lead to vascular leakage and pulmonary 
oedema [66].  
 
Another relatively common pro-inflammatory state after blood transfusion is febrile non-
hemolytic transfusion reaction (FNHTR) that is either mediated by pro-inflammatory 
cytokines that accumulate during storage or by previously formed leukocyte antibodies in the 
patient or antibodies contained in the donor’s blood units. The overall incidence of febrile 
non-hemolytic transfusion reactions has decreased significantly since leukoreduction has been 
implemented [67]. 
 
 
3. Clinical studies on transfusion-related immunomodulation 
 
Particular to transfusion medicine is that results from clinical studies are quite difficult to 
analyse and interpret according to the mostly heterogeneous study populations, the lack of a 
universally applied transfusion trigger and blood product manufacturing that differs from one 
country to the other. More specifically, in North America a WBC-containing ABT means 
unmodified (or “buffy-coat-rich”) RBCs, whereas in Europe patients normally receive buffy-
coat-reduced RBCs.  
By buffy-coat reduction approximately 75% of the donor’s WBCs are removed by 
centrifugation and extraction of the whitish layer in between the plasma and red blood cell 
layers. Only leukocyte reduction by filtration reduces the number of transfused leukocytes per 
RBC unit from approximately 10^9 to less than 5 x 10^6. Through leukocyte filtration there is 
a loss of less than 10% of RBCs and an additional cost of about $35 per unit.  
 
TRIM is known to occur unequivocally, but its clinical significance remains controversial. 
The contribution of WBCs as a causal agent of TRIM is heavily debated. Assuming that 
mononuclear cells with cell-bound HLA-antigens are the main responsible constituents of 
immunomodulation we would expect a better outcome in patients that receive WBC-depleted 
blood products or autologous transfusions.  A TRIM effect by transfusion of soluble HLA 
peptides would only be prevented by autologous blood, whereas soluble biologic response 
modifiers could be quantitatively reduced by pre-storage WBC reduction or transfusion of 
fresh autologous blood. Any differences in outcomes reported following the implementation 
of pre-storage WBC reduction in “before-and-after” studies can therefore be attributed to 
allogeneic mononuclear cells and / or WBC-derived soluble mediators, because the patients 
transfused before or after implementation of WBC reduction differed only in their exposure to 
WBCs.  
 
Vamvakas et al. [68] categorize in their review the twenty-two available randomized 
controlled trials based on the inference that they permit about possible mediators of TRIM, 
and examine the strength of evidence available for relying on WBC reduction or autologous 
transfusion to prevent TRIM effects (i.e. higher overall mortality risk, higher rate of infectious 
complications, higher cancer recurrence rate).  
Through all randomized controlled trials only in cardiac surgery the findings were conclusive 
for a deleterious TRIM effect of WBC-containing RBCs with a higher short-term (up to three 
month post transfusion) mortality rate [69], [70], [71]. Though, even in this setting, the 
reasons for the excess deaths attributed to WBC-containing ABTs remain elusive. The initial 
hypothesis was that WBC-containing ABTs may predispose more than leukoreduced ABT to 
multiple organ failure which, in turn, may predispose to mortality. However, up to now, no 
randomized controlled trial has demonstrated a higher incidence of multiple organ failure or 
any particular cause of death in WBC-containing compared to leukoreduced ABTs. The 
available randomized controlled trials did not show any increased risk of postoperative 
infection rate or cancer recurrence in WBC-containing ABTs, either.  
In the large meta-analysis of Vamvakas et al. no benefit from autologous transfusion in 
preventing adverse TRIM effects could be found. This is probably due to the long storage 
time (4 to 6 weeks) autologous blood is usually subjected to. Storage lesions and the 
accumulation of biologic response modifiers through time seem to abolish the expected 
advantage of autologous over allogeneic blood. 
 
One reason for the lack of significant differences in outcome between recipients of 
leukoreduced and WBC-containing blood products may be the fact that randomisation was 
mostly performed at hospital entry and not only prior to blood component transfusion. From 
this follows that, in both groups, patients that did not receive any blood transfusion, may have 
diluted a potential clinical benefit of leukoreduction.  
Limiting meta-analyses to patients who actually received transfusions, Blumberg et al. [72] 
could demonstrate that leukoreduced transfusions significantly reduced the summary odds 
ratio of postoperative infection (odds ratio 0.52; 95% confidence interval: 0.33-0.82). In a 
study by Fergusson et al. [73] the pooled relative risk ratio for transfused patients in regard of 
postoperative infection was 0.60 (95% confidence interval: 0.38-0.93), although the overall 
mortality rate remained unchanged by leukoreduction. 
 
Retrospective cohort studies that were performed with data from before and after 
implementation of universal leukoreduction show controversial results. No clear statement 
can be made whether universal leukoreduction was indeed associated with any clinical 
advantage with regard of overall mortality rate, infection rate, or cancer recurrence [74], [75], 
[76], [77], [78].  
 
 
To summarize, we conclude that, despite all the published data available today, it still remains 
unproven that leukoreduction improves morbidity or mortality. Future trials should only 
randomize patients after a decision is made to transfuse. Since in Western Europe and North 
America the majority of blood transfusions are now leukoreduced, the undertaking of further 
randomized controlled trials comparing recipients of WBC-containing ABTs with recipients 
of leukoreduced ABTs is yet unlikely. 
However, several reasons support the implementation of universal leukoreduction without 
statistical proof: 1) There are some data suggesting benefit; 2) Risks associated with 
leukoreduction are extremely low; 3) There is no apparent benefit of transfusing the white 
cells that are filtered; 4) Leukoreduction reduces febrile non-hemolytic transfusion reactions, 
primary alloimmunization to human leukocyte antigens and refractoriness to random-donor 
platelet transfusions, and last but not least reduces primary transmission of CMV and other 
infections due to WBC-associated pathogens.  
 
 
4. Nosocomial infections 
 
Transfusion of RBCs, independent of WBC count, has emerged as a potential risk factor for 
nosocomial infection in intensive care patients, trauma patients and cardiovascular surgery 
patients. Although the exact pathomechanism remains unclear, some sort of TRIM effect 
seems to be the underlying precondition. 
 
Taylor et al. [42] assessed 1717 patients admitted to a 40-bed medical-surgical-trauma ICU. 
Nosocomial infection rate was 15.4% in the transfusion group versus 2.9% in the non-
transfusion group. A dose-response pattern was apparent, the risk of infection being greater, 
the more blood units a patient received. For each unit of blood received the odds ratio of 
developing a nosocomial infection increased by a factor of 1.5. Transfusion was also 
associated with both increased length of stay in the ICU and in the hospital and higher 
mortality rates.   
In a consecutive study with 2085 patients enrolled, Taylor et al. [79] confirmed their previous 
findings, the incidence of nosocomial infections being significantly higher in transfused 
(14.3%) than in non-transfused (5.8%) patients, independent of their predicted survival 
probability.  
Claridge et al. [80] investigated 1593 consecutive adult patients admitted to a level I trauma 
centre. The infection rate in patients who received at least one unit of RBCs was 33.0% versus 
7.6% in patients who did not receive any transfusion. They also reported a linear correlation 
between the number of transfused blood units and the incidence of infection.  
As the two studies mentioned before, Banbury et al. [81] and Sreeram et al. [82] found an 
increased rate of infections in cardiac surgical patients receiving RBC transfusions.  
Shorr et al. [83] looked at the relationship between RBC transfusion and ICU-acquired 
bloodstream infection in 4892 patients in 284 adult ICUs across the United States. A total of 
3.3% of the study population developed an ICU-acquired bloodstream infection. Using a 
multivariate analysis adjusting for severity of illness, primary diagnosis, use of mechanical 
ventilation, placement of central venous catheters, and ICU length of stay, three variables 
were independently associated with diagnosis of a new bloodstream infection: a) baseline 
treatment with cephalosporins, b) higher organ failure assessment score, and c) RBC 
transfusion. In a secondary analysis of this same cohort, they noted that transfusion 
independently increased the risk for ventilator-associated pneumonia (odds ratio 2.16; 95% 
confidence interval: 1.27-3.66) as well in a positive dose-response relationship.  
 
Hill et al. [84] evaluated in a meta-analysis of twenty peer-reviewed articles the association 
between blood transfusion and postoperative infection. In line with the above mentioned data, 
they found a direct correlation between postoperative infection rate and blood transfusion.  
 
 
 
A restrictive strategy for transfusion of RBCs has been shown to be associated with equal or 
superior outcome to a liberal transfusion strategy [6]. A lower thrombocyte transfusion 
threshold has been shown to be safe in terms of bleeding complications and even superior in 
order to prevent alloimmunization and refractoriness to platelet transfusion [85]. Most clinical 
uses of fresh frozen plasma, even those currently recommended by practice guidelines, are not 
supported by evidence from randomized clinical trials [86]. 
A clear benefit of a liberal transfusion strategy missing, a risk of transfusion-transmitted 
infection still existing (by primarily infected or secondarily contaminated blood products), 
and evidence ever growing of transfusion-related immunomodulation with a higher incidence 
of nosocomial infections in transfused patients, we really need very good arguments to still 
deliberately transfuse our patients. 
Practice Points:  
• Transfusion-related immunomodulation is known to occur unequivocally, but its 
clinical significance remains controversial. 
• The precise pathomechanism of transfusion-related immunomodulation is not yet 
understood: There is evidence that allogeneic blood transfusions may either cause 
alloimmunization, tolerance, or immunosuppression. However, research on 
transfusion-related acute lung injury raised the suspicion that allogeneic blood 
transfusions may rather induce a pro-inflammatory state. 
• The specific immunomodulatory constituents are still unknown, though several are 
highly suspected: allogeneic mononuclear cells, HLA peptides, and soluble biologic 
response modifiers.  
• The contribution of white blood cells as a causal agent of transfusion-related 
immunomodulation was subject of recently published meta-analysis. Though the 
results were rather confounding and permitted no clear statement on a possible benefit 
of leukoreduction on overall mortality, infectious complications, or cancer recurrence 
rate. 
• There is clear evidence that leukoreduction reduces febrile non-hemolytic transfusion 
reactions and primary alloimmunization to human leukocyte antigens with 
refractoriness to random-donor platelet transfusions. However, leukoreduction failed 
to reduce the incidence of transfusion-related microchimerism and transfusion-
associated graft-versus-host disease. 
• Transfusion of RBCs, independent of WBC count, has emerged as a potential risk 
factor for nosocomial infection 
 
 
 
Research Agenda: 
• Further research is warranted to understand the exact pathomechanism of transfusion-
related immunomodulation 
• Further randomized controlled trials are needed to elucidate the role of donor white 
blood cells in the pathogenesis of transfusion-related immunomodulation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary 
In the last decades the risk of acquiring a transfusion-transmitted infection has declined 
substantially. After human immunodeficiency virus and hepatitis B and C virus transmission 
were successfully reduced, due to a rising number of immunocompromised transfusion 
recipients, cytomegalovirus has become an important issue in transfusion medicine. Besides 
that new pathogens are threatening the safety of blood supply (i.e. West Nile virus, TT virus, 
SEN virus). Although relatively rare in Western Countries, on a global scale, malaria is one of 
the most common transfusion-transmitted infections. Despite new standards in blood product 
manufacturing and storage, bacterial contamination still remains a considerable cause of 
transfusion-related morbidity and mortality. 
Transfusion-related immunomodulation is known to occur unequivocally, but its clinical 
significance remains controversial and its pathomechanism is not yet precisely understood. 
There is evidence that allogeneic blood transfusions may either cause alloimmunization, 
tolerance, or immunosuppression. However, research on transfusion-related acute lung injury 
indicates that allogeneic blood transfusions may induce a pro-inflammatory state. The specific 
immunomodulatory constituents are still unknown, though allogeneic mononuclear cells, 
HLA peptides, and soluble biologic response modifiers are highly suspected. The contribution 
of white blood cells as a causal agent of transfusion-related immunomodulation remains 
uncertain and no clear statement on a possible benefit of leukoreduction on overall mortality, 
infectious complications, or cancer recurrence rate is possible today. However, nosocomial 
infections are more frequent in transfused than in non-transfused patients. 
Transfusing blood products remains potentially harmful and thus should be reduced to a very 
minimum, also in the light of transfusion-related infectious complications. 
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